Lifecycle Immunogenicity Management.
Immunogenicity documentation plays a central role in regulatory success. Across development and commercialization, sponsors are expected to proactively assess, monitor, and clearly communicate immunogenicity risk. These documents reflect your strategy; demonstrating how risks were identified, uncertainties addressed, and clinical impact evaluated, giving regulators confidence that immunogenicity is well understood and appropriately managed.
EpiVax offers expert consulting for Immunogenicity Risk Assessment (IRA) and Integrated Summaries of Immunogenicity (ISI) writing, supporting the development of cohesive, regulator-ready submission packages. Our consultants review and interpret data across all phases to develop defensible narratives on predicted and observed risk, mitigation strategies, bioanalytical and clinical approaches, and safety and efficacy impact. As part of a lifecycle immunogenicity strategy, we integrate computational and experimental data directly into these documents and provide tailored recommendations for additional assessments when needed to strengthen your submission.
Immunogenicity Risk Assessment (IRA)
The IRA establishes the scientific and strategic framework for immunogenicity management early in development and is updated as programs advance.
Our support includes:
- Risk factor identification and structured classification
- Integration of in silico T cell epitope prediction and related computational analyses
- Interpretation of in vitro immunogenicity data to contextualize predicted risk
- Identification and management of early-stage uncertainty
- Development of risk-based bioanalytical, nonclinical, and clinical monitoring strategies
- Recommendations for additional studies to address data gaps and support regulatory positioning
Integrated Summary of Immunogenicity (ISI)
The ISI brings the lifecycle story together, integrating prior risk assessments with accumulated clinical experience to clearly articulate immunogenicity impact. Includes:
- Consolidated analysis integrating IRA conclusions, bioanalytical strategy, and clinical outcomes
- Evaluation of incidence, persistence, neutralizing antibody responses, and clinical relevance
- Assessment of impact on safety, efficacy, pharmacokinetics, and pharmacodynamics
- Integration of supportive in silico and in vitro findings where appropriate
- Development of a clear, defensible safety and efficacy impact narrative
- Strategic positioning of immunogenicity data within the broader regulatory submission
Rigorous Documentation
Immunogenicity sections grounded in deep technical expertise, ensuring clarity, internal consistency, and regulatory alignment.
Lifecycle Immunogenicity Strategy
Integrated support from early risk identification through clinical data interpretation and post-approval updates.
On-Time Delivery
Focused expertise that keeps critical immunogenicity documents on schedule and aligned with program milestones.
Global Regulatory Insight
Experience supporting submissions to FDA, EMA, and other global agencies, with documentation tailored to current expectations.
With deep expertise in computational and experimental immunology, EpiVax delivers documentation that reflects both scientific rigor and practical regulatory insight.
If your team is preparing an IRA or ISI and wants experienced, immunology-focused support across the full product lifecycle, we are ready to collaborate.
